SCALE UP DRUG SCREENING
Safer Therapies With Advanced Cardiotoxicity Screening
Eliminate Cardiotoxic Compounds Earlier In The Drug Discovery Process
The rise in cardiotoxicity cases among patients with existing heart conditions, coupled with the increasing prevalence of cardiovascular diseases globally, gave rise to more drug safety concerns. The need to identify harmful components early has never been more critical.
Yet there are challenges, such as conducting efficient cardiotoxicity screening and navigating stringent regulatory landscapes. Good news! Our groundbreaking technology can help you address these challenges head-on, empowering you to accelerate your discoveries and reducing time and cost.
More Human-Relevant Models
Human induced pluripotent stem cell iPSC derived cardiomyocytes are especially attractive cell models for cardiotoxicity testing
High-Throughput Kinetic Screening
Measure 384 samples in minutes rather than hours, and screen up to 32,000 compounds per day for in vitro cytotoxicity, CiPA assays, and more with the FLIPR® Penta High-Throughput Cellular Screening System.
Customized Protocols and Data Analysis
Analyze peaks of iPSCs, differentiated into cardiomyocytes up to 100 times per second and quickly cherry pick events such as EAD-like events, fibrillation, and irregular beating with the ScreenWorks® Peak Pro Software.
Robust Assay Kits
FLIPR Assay Kits provide the most comprehensive method for assesing intracellular calcium changes, potassium channels (including hERG channels), and membrane potential in a simple and reliable homogeneous assay format.
Full Regulatory Compliance
Achieve Full FDA 21 CFR Part 11 and EudraLex Annex 11 Compliance with Software Validation. Reduce the cost and time of validation by 50% compared to using multiple platforms to collect and analyze data with SoftMax Pro GxP Compliance Software.
Discover a Powerful Workflow for Testing Potential Cardiotoxic Effects of Drugs
2D cell models are commonplace, yet human beings are three-dimensional, and being able to represent true physiology paves the way for more effective screening. Watch Dr Simon Lydford, application scientist at Molecular Devices, present a new powerful workflow for testing the potential cardiotoxic effects of drugs.
